ArticleCureus2025
Philadelphia Chromosome-Negative Hyperdiploid B-cell Acute Lymphoblastic Leukemia Presenting As Hemophagocytic Lymphohistiocytosis in a Young Adult: A Case Report.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hemophagocytic lymphohistiocytosis (HLH) is a rare, life-threatening hyperinflammatory syndrome that can mask underlying malignancies. We report a 22-year-old woman who presented with fatigue, night sweats, pancytopenia, hyperferritinemia, and abnormal liver function tests, without peripheral blasts. Imaging revealed no organomegaly or significant lymphadenopathy. Initial evaluation suggested HLH or severe infection. Bone marrow biopsy confirmed Philadelphia chromosome-negative, hyperdiploid B-cell acute lymphoblastic leukemia (B-ALL). The patient received supportive care with intravenous antibiotics, growth factor support, and tumor lysis prophylaxis. She commenced induction chemotherapy with the UKALL14 Regimen B protocol. Hyperinflammation was controlled with corticosteroids, and she remained clinically stable during induction. This case highlights the diagnostic challenge of malignancy-associated HLH, particularly when peripheral blasts are absent and imaging is non-specific. Masked leukemia presentations can delay recognition of the underlying cancer, leading to treatment delays. High hyperdiploidy usually confers a favorable prognosis, but its association with HLH is rare. Clinicians should consider early bone marrow evaluation in young adults with unexplained cytopenias, systemic inflammation, and markedly elevated ferritin, even in the absence of peripheral blasts. Prompt diagnosis and timely initiation of chemotherapy are critical to improve outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.